Cholesterol, copper and Aβ in controls, MCI, AD and the AD cholesterol-lowering treatment trial (ADCLT)

Current Alzheimer Research

Volumn 2, Issue 5, 2005, Pages 527-539

  Sparks, D Larry ^a   Petanceska, Suzana ^b,c   Sabbagh, Marwan ^a   Connor, Donald ^a   Soares, Holly ^d   Adler, Charles ^e   Lopez, Jean ^a   Ziolkowski, Chuck ^a   Lochhead, Jeff ^f   Browne, Patrick ^g  

^a SUN HEALTH RESEARCH INSTITUTE   (United States)

^b NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^c NEW YORK UNIVERSITY   (United States)

^d PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^e MAYO CLINIC   (United States)

^f ARIZONA STATE UNIVERSITY   (United States)

^g Sun Health Boswell Hospital   (United States)

Author keywords

AD; Cholesterol; Clinical trial; Copper; MCI

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; ANTILIPEMIC AGENT; APOLIPOPROTEIN E; ATORVASTATIN; CERULOPLASMIN; CHAPERONE; COPPER; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); CHOLESTEROL; CHOLINERGIC RECEPTOR BLOCKING AGENT; HEPTANOIC ACID DERIVATIVE; PEPTIDE FRAGMENT; PYRROLE DERIVATIVE;

AGED; ALZHEIMER DISEASE; CERULOPLASMIN BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL EXAMINATION; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DEPRESSION; EDUCATION; HUMAN; LEARNING TEST; MINI MENTAL STATE EXAMINATION; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECALL; REVIEW; TASK PERFORMANCE; VERBAL MEMORY; ADULT; ARTICLE; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CROSS-SECTIONAL STUDY; LEARNING; LONGITUDINAL STUDY; METABOLISM; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; CERULOPLASMIN; CHOLESTEROL; CHOLINERGIC ANTAGONISTS; COGNITION DISORDERS; COPPER; CROSS-SECTIONAL STUDIES; HEPTANOIC ACIDS; HUMANS; LONGITUDINAL STUDIES; MIDDLE AGED; PEPTIDE FRAGMENTS; PYRROLES; VERBAL LEARNING;

EID: 28244484884     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720505774932296     Document Type: Review

References (116)

1. Sparks DL, Hunsaker JC, Scheff SW, Kryscio RJ, Henson JL, Markesbery WR. Cortical senile plaques in coronary artery disease, aging and Alzheimer's disease. Neurobiol Aging 11:601-607 (1990).
2. Sparks DL, Scheff SW, Hunsaker III JC, Liu H, Landers T, Gross DR. Induction of Alzheimer-like β-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp Neurol 126:88-94 (1994).
3. Bodovitz S, Klein WL. Cholesterol modulates alpha-secretase cleavage of amyloid precursor protein. J Biol Chem 271(8):4436-4440 (1996).
4. Katzman R. A neurologist's view of Alzheimer's disease and dementia. Int Psychogeriatr 16(3):259-273 (2004).
5. Miller LJ, Chacko R. The role of cholesterol and statins in Alzheimer's disease. Ann Pharmacother 38(1):91-98 (2004).
6. Reiss A, KA, Rahman M, Dhan E, Ghiso J, de Leon M. Cholesterol in neurologic disorders of the elderly: stroke and Alzheimer's disease. Neurobiol Aging 25(8):977-989 (2004).
7. Teter B. ApoE-dependent plasticity in Alzheimer's disease. J Mol Neurosci 23(3):167-179 (2004).
8. Burns M, Duff K. Cholesterol in Alzheimer's disease and tauopathy. Ann N Y Acad Sci 977:367-375 (2002).
9. Wolozin B, Brown Jr, Theisler C, Silberman S. The cellular biochemistry of cholesterol and statins: insights into pathophysiology and therapy of Alzheimer's disease. CNS Drug Rev 10(2):126-146 (2004).
10. Poirier J. Apolipoprotein E and cholesterol metabolism in the pathogenesis treatment of Alzheimer's disease. Trends Mol Med 9(3):94-101 (2003).
11. Kolsch H, Lutjohann D, von Bergmann K, Heun R. The role of 24S-hydroxycholesterol in Alzheimer's disease. J Nutr Health Aging 7(1):37-41 (2003).
12. Gibson Wood W, Eckert GP, Igbavboa U, Muller WE. Amyloid beta-protein interactions with membranes and cholesterol causes or casualties of Alzheimer's disease. Biochim Biophys Acta 1619(2):281-290 (2003).
13. Michikawa M. Cholesterol paradox: is high total or low HDL cholesterol level for Alzehimer's disease? J Neurosci Res 72(2):141-146 (2003).
14. Lehtonen A, Luutonen S. High-density lipoprotein cholesterol levels of very old people in the diagnosis of dementia. Age and Ageing 15:267-270 (1986).
15. Giubilei F, D'Antona R, Antonini R, Lenzi GL, Ricci G, Fieschi C. Serum lipoprotein pattern variations in dementia and ischemic stroke. Acta Neurol Scand 81:84-86 (1990).
16. Czech C, Forstl H, Hentschel F, et al. Apolipoprotein E-4 gene dose in clinically diagnosed Alzheimer's disease: Prevalence, plasma cholesterol levels and cerebrovascular change. Eur Arch Psychiatry Clin Neurosci 243:291-292 (1994).
17. Jarvik GP, Wijsman EM, Kukull WA, Schellenberg GD, Yu C, Larson EB. Interactions of apolipoprotein E genotype, total cholesterol level, age, sex in prediction of Alzheimer's disease: A case-control study. Neurology 45:1092-1096 (1995).
18. Mahieux F, Couderc R, Moulignier A, Bailleul S, Podrabinek N, Laudet J. Isoform 4 of apolipoprotein E and Alzheimer disease. Specificity and clinical study. Rev Neurol (Paris) 151(4):231-239 (1995).
19. Sparks DL. Coronary Artery Disease, Hypertension, ApoE, and Cholesterol: A link to Alzheimer's Disease? Ann N Y Acad Sci 826:128-146(1997).
20. Grant WB. Dietary links to Alzheimer's disease. Alzei Dis Rev 2:42-55 (1997).
21. Desmond DW, Tatemichi TK, Paik M, Stern Y. Risk factors for cerebrovascular disease as correlates of cognitive function in a stroke-free cohort. Arch Neurol 50:162-166 (1993).
22. Kuo Y-M, Emmerling MR, Bisgaier CL, Essenburg AD, Lampert HC, Roher AE. Elevated low-density lipoprotein in Alzheimer's disease correlates with brain A-beta 1-42 levels. BBRC 252(3):711-715 (1998).
23. Chandra V, Pandav R. Gene-environment interaction in Alzheimer's disease: A potential role for cholesterol. Neuroepidemiology 17(5):225-232 (1998).
24. Notkola I-L, Sulkava R, Pekkanen J, et al Serum total cholesterol, apolipoprotein Eepsilon4 allele, and Alzheimer's disease. Neuroepidemiol 17:14-20(1998).
25. Olson RE. Discovery of the lipoproteins, their role in fat transport and their significance as risk factors. J Nutr 128(2 Suppl):439S-443S (1998).
26. Kalmijn S, Launer LJ, Ott A, Witteman JCM, Hofman A, Breteler MMB. Dietary fat intake and the risk of incident dementia in the Rotterdam study. Ann Neurol 42:776-782 (1997).
27. Kuusisto J, Koivistom K, Mykkanen L, et al. Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein E4 phenotype: Cross sectional population based study. BMJ 315:1045-1049 (1997).
28. Kivipelto M, Helkala E-L, Hallikainen M, et al. Elevated systolic blood pressure and high cholesterol levels at midlife are risk factors for late-life dementia. Neurobiol Aging 21(1S):S174 (2000).
29. Yasojima K, Mcgeer EG, Mcgeer PI. HMG Co-A reductase mRNA in AD and control brain. Neuroreport 12:2935-2938 (2001).
30. Sparks DL, Liu H, Gross DR, Scheff SW. Increased density of cortical Apolipoprotein E immunoreactive neurons in rabbit brain after dietary administration of cholesterol. Neurosci Lett 187:142-144 (1995).
31. Sparks DL. Intraneuronal β-amyloid immunoreactivity in the CNS. Neurobiol Aging 17(2):291-299(1996).
32. Sparks DL. Dietary cholesterol,induces Alzheimer-like β-amyloid immunoreactivity in rabbit brain. Nutr Metab Cardiovasc Dis 7(3):255-266(1997).
33. Streit WJ, Sparks DL. Activation of microglia in the brains of humans with heart disease and hypercholesterolemic rabbits. J Mol Med 75:130-138 (1997).
34. Sparks DL. Neuropathologic links between Alzheimer's disease and Vascular disease. In: Iqbal K, Swaab DF, Winblad B, Wisniewski HM, ed. Alzheimer's Disease and Related disorders. John Wiley & Sons Ltd, 1999: 153-163. vol 6).
35. Sparks DL, Kou Y-M, Roher A, Martin TA, Lukas RJ. Alterations of Alzheimer's disease in the cholesterol-fed rabbit, including vascular inflammation. Preliminary observations. NY Acad Sci 903:335-344 (2000).
36. Shie F-G, Jin L-W, Cook DG, Leverenz JB, LeBoeul RC. Diet-induced hypercholesterolemia enhances brain Aβ accumulation in transgenic mice. NeuroReport 13:455-459 (2002).
37. Fishman CE, White SL, DeLong CA, et al. High fat diet potentiates β-amyloid deposition in the APP V717F transgenic mouse model of Alzheimer's disease. Soc Neurosci 25:1859 (1999).
38. Bales KR, Fishman C, DeLong C, Du Y, Jordan W, Paul SM. Diet-induced hyperlipidemia accelerates amyloid deposition in the APPv717f transgenic mouse model of Alzheimer's disease. Neurobiol Aging 21(1S):S139 (2000).
39. Refolo LM, Pappolla MA, Malester B, et al. Hypercholesterolemia accelerates Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis 7(4):321-331 (2000).
40. Kirsch C, Eckert GP, Koudinov AR, Muller WE. Brain cholesterol, statins and Alzheimer's Disease. Pharmacopsychiatry 36 Suppl 2:s113-s119(2003).
41. Levin-Allerhand JA, Lominska CE, Smith JD. Increased amyloid-levels in APPSWE transgenic mice treated chronically with a physiological high-fat high-cholesterol diet. J Nutr Health Aging 6:315-319(2002).
42. Racchi M, Baetta R, Salvietti N, et al. Secretory processing of amyloid precursor protein is inhibited by increase in cellular cholesterol content. Biochem J 322:893-898 (1997).
43. Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, Simons K. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci (USA) 95(11):6460-6464(1998).
44. Frears ER, Stephens DJ, Walters CE, Davies H, Austen BM. The role of cholesterol in the biosynthesis of β-amyloid. NeuroReport 10:1699-1705(1999).
45. Galbete JL, Martin TR, Peressini E, Modena P, Bianchi R, Forloni G. Cholesterol decreases secretion of the secreted form of amyloid precursor protein by interfering with glycosylation in the protein secretory pathway. Biochem J. 348(Pt 2):307-313 (2000).
46. Austen BM, Frears ER, Davies H. Cholesterol upregulates production of Abeta 1-40 and 1-42 in transfected cells. Neurobiol Aging 21(1S):S254(2000).
47. Beyreuther K. Physiological function of APP processing. Neurobiol Aging 21(1S):S69 (2000).
48. Urmoneit B, Turner J, Dyrks T. Cationic lipids (lipofectamine) and disturbance of cellular cholesterol and sphinglmyelin distribution modulates gamma-secretase activity within amyloid precursor protein in vitro. Prostoglandins Other Lipid Metiat 55(5-6):331-343 (1998).
49. Bergmann C, Runz H, Jakala P, Hartmann T. Diversification of gamma-secretase versus beta-secretase inhibition by cholesterol depletion. Neurobiol Aging 21(1S):S278 (2000).
50. Fassbender K, Simons M, Bergmann C, et al. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. PNAS 98(10):5371-5373 (2001).
51. Michikawa M, Yanagisawa K. Apolipoprotein E4 induces neuronal cell death under conditions suppressed de novo cholesterol synthesis. J Neurosci Res 54(1):58-67 (1998).
52. Sparks DL, Connor DJ, Browne PJ, Lopez JE, Sabbagh MN. HMG-CoA reductase inhibitors (statins) in the treatment of Alzheimer's disease and why it would be ill-advised to use one that crosses the blood-brain barrier. J Nutr Health Aging 6(5):324-331 (2002).
53. Refolo LM, Pappolla MA, LaFrancois J, et al. A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol Dis 5:890-899 (2001).
54. Petanceska SS, DeRosa S, Olm V, et al. Statin therapy for Alzheimer's Disease. Will it work? J Mol Neurosci 19:155-161 (2002).
55. Park IH, Hwang EM, Hong HS, et al. Lovastatin enhances Abeta production and senile plaque deposits in female TÊ2576 mice. Neurobiol Aging 24(5):637-643 (2003).
56. Chauhan N, Siegel G, Feinstein D. Effects of lovastatin and pravastatin on amyloid processing and inflammatory response in TgCRND8 brain. Neurochem Res 29(10): 1897-1911 (2004).
57. Puglielli L, Konopaka G, Pack-Chung E, etal. Acyl-coenzyme A: Cholesterol acyltranferase modulates the generation of the amyloid beta-peptide. Nat Cell biol 3(10):905-912 (2001).
58. Puglielli L, Tanzi RE, Kovacs DM. Alzheimer's disease: the cholesterol connection. Nature Neuroscience 6(4):345-351 (2003).
59. Puglielli L, Ellis BC, MacKenzie Ingano LA, Kovacs DM. Role of Acyl-Coenzyme A: Cholesterol acyltransferase activity in the processing of amyloid precursor protein. J Mol Neurosci 24:93-96 (2004).
60. Petanceska SS, DeRosa S, Sharma A, et al. Changes in apolipoprotein E expression in response to dietary and pharmacological modulation of cholesterol. J Mol Neurosci 20(3):395-406 (2003).
61. Petanceska S, Papolla M, Refolo M. Modulation of Alzheimer's Amyloidosis by Statins: Mechanisms of Action. Crit Rev Med Chem 3:1-7(2003).
62. Pedrini S, Carter TL, Prendergast G, Petanceska S, Ehrlich ME, Gandy S. Modulation of Statin-activiated shedding of Alzheimer APP ectodomain by ROCK. PLoS Med 2(1): e18 (2005).
63. Wolozin B, Kellman W, Ruosseau P, Celesia G, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol Oct; 57(10): 1439-1443 (2000).
64. Jick H, Zornberg G, Jick S, Seshadri S, Drachman D. Statins and the risk of dementia. Lancel 11:356(9242): 1627-1631 (2000).
65. Yaffe K, Barrett-Connor E, Lin F, Grady D. Serum lipoprotein levels, statin use, and cognitive function in older women. Arch Neurol 59:378-384 (2002).
66. Rockwood K, Kirkland S, Hogan DB, et al. Use of Lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol 59:223-227 (2002).
67. Zamrini E, McGwin G, Roseman JM. Association between statin use and Alzheimer's disease. Neuroepidemiology 23(1-2):94-98 (2004).
68. Li G, Higdon R, Kukull W, et al. Statin therapy and risk of dementia in the elderly: a community based prospective cohort study. Neurology 63(9):1624-1628 (2004).
69. Zandi P, Sparks DL, Khachaturian AS, et al. Do Statins Reduce Risk of Incident Dementia and AD? The Cache County Study. Arch Gen Psychiatry 62:217-224 (2005).
70. Tokuda T, Takaoka A, Matsuno S, Sakuria S, Shimada H, Morita H. Plasma levels of amyloid beta did not differ between subjects taking statins and those not taking statins. Ann Neurol 49:546-547 (2001).
71. Friedhoff LT, Cullen EI, Geoghagen NS, Buxbaum JD. Treatment with controlled-release lovastatin decreases serum concentrations of human beta-amyloid (A beta) peptide. Int J Neuropsychopharmacol 4:127-130 (2001).
72. Buxbaum JD, Cullen EI, Friedhoff LT. Pharmacological concentrations of the HMG-CoA reductatse inhibitor lovastatin decrease the formation of the Alzheimer beta-amyloid peptide in vitro and in patients. Front Biosci 7:a50-a59 (2002).
73. Simons M, Schwarzler F, Lutjohann D. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26 week, randomized, placebo controled, double-blind trial. Ann Neurol 52:346-350 (2002).
74. Lutjohann D, von Bergmann K. 24S-hydroxycholesterol: a marker of brain cholesterol metabolism. Pharmacopsychiatry 36 Supp12:s102-s106(2003).
75. Ishii K, Tokuda T, Matsushima T, et al. Pravastatin at 10 mg/day does not decrease plasma levels of either amyloid-beta (Abeta) 40 or Abeta 42 in humans. Neurosci Lett Oct 30; 350(3): 161-164 (2003).
76. Baskin F, Rosenberg RN, Fang X, et al. Correlation of statin-increased platelet APP ratios and reduced lipids in AD patients. Neuroloty 60(12):2006-2007 (2003).
77. Vega GL, Weiner MF, Lipton AM, et al. Reduction in Levels of 24S-Hydroxycholesterol by Statin Treatment in Patients with Alzheimer Disease. Arch Neurol 60:510-514 (2003).
78. Sjogren M, Gustafsson K, Syversen S, et al. Treatment with simvastatin in patients with Alzheimer's disease lowers both alpha- and beta-cleaved amyloid precursor protein. Dement Geriatr Cogn Disord 16(1):25-30 (2003),
79. Hoglund K, Wikiund O, Vanderstichele H, Eikenberg O, Vanmechelen M, Blennow K. Plasma levels of beta-amyloid(1-40), beta-amyloid(1-42), and total beta-amyloid remain unaffected in adult patients with hypercholesterolemia after treatment with statins. Arch Neurol 61:333-337 (2004).
80. Sparks DL, Connor DJ, Wasser DR, Lopez JE, Sabbagh MN. The Alzheimer's Disease Atorvastatin Treatment Trial: Scientific basis and position on the use of HMG-CoA reductase inhibitors (statins) that do or do not cross the blood-brain barrier. In: Advances in Drug discovery and Drug Development for Cognitive Aging and Alzheimer's Disease. Springer Publishing Co., 2000: 244-252.
81. Sparks DL, Martins R, Martin T. Cholesterol and cognition: Rationale for the AD Cholesterol-lowering Treatment Trial and sex-related differences in β-amyloid accumulation in the brains of spontaneously hypercholesterolemic Watanabe rabbits. Ann N Y Acad Sci 977:356-366 (2002).
82. Sparks DL, Sabbagh MN, Connor DJ, et al. Atorvastatin for the Treatment of Mild-to-Moderate Alzheimer's Disease: Preliminary Results. Arch Neurol 62:753-757 (2005).
83. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State:" A practical method for grading the mental state of patients for the clinician. J Psychiatric Res 12:189-198 (1975).
84. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's Disease. Am J Psychiatry 141:11-19 (1984).
85. Kaufer DI, Cummings JL, Cristine EL. Assessing the impact of neuropsychiatric symptoms in Alzheimer's disease: The Neuropsychiatrie Inventory Caregiver distress Scale. J Amer Geriatr Soc 46:210-215(1998).
86. Schneider LS, Olin JT, Doody RS, et al. Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 11(Suppl 2):S22-S32 (1997).
87. Galasko D, Corey-Bloom J, Thal LJ. Monitoring progression in Alzheimer's disease. J Am Geriatr Soc 39(9):932-941 (1991).
88. Galasko D, Bennett D, Sano M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 11(Suppl2):S33-S39(1997).
89. Yesavage JA. Geriatric Depression Scale. Psychopharmacol Bull 24(4):709-711(1988).
90. Sparks DL, Sabbagh MN, Connor DJ, et al. Atorvastatin therapy lowers circulating cholesterol but not free radical activity in advance of identifiable clinical benefit in the treatment of mild-to-moderate AD. Curr AD Res 2(3):343-353 (2005).
91. Sparks DL, Lochhead J, Horstman D, Wagoner T, Martin T. Water quality has a pronounced effect on cholesterol-induced accumulation of Alzheimer Amyloid β(Aβ) in rabbit brain. JAD 4:523-529 (2002).
92. Sparks DL, Schreurs BG. Trace amounts of copper in water induce β-amyloid plaques and learning deficits in a rabbit model of alzheimer's disease. PNAS 100(19):1065-1069 (2003).
93. Waggoner DJ, Bartnikas TB, Gitlin JD. The role of copper in neurodegenerative disease. Neurobiol Dis 6:221-230 (1999).
94. Iskra M, Majewski W. Copper and zinc concentration and the activities of ceruloplasmin and Superoxide dismutatse in atherosclerosis obliterans. Bil Trace Elem Res 73:55-65 (2000).
95. Piorunska-Stolzman M, Iskra M, Majewski W. The activity of cholesterol esterase and ceruloplasmin are inversely related in the serum of men with atherosclerosis obliterans. Med Sci Monit 7:940-945(2001).
96. Squitti R, Lupoi D, Pasqualetti P, et al. Elevation of serum copper levels in Alzheimer's disease. Neurology 59(8):1153-1161 (2002).
97. Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST. Practice parameter: Early detection of dementia: Mild cognitive impairment (an evidence-based review). Report of the Quality Standard Subcommittee of the American Academy of Neurology. Neurology 56:1133-1142 (2001).
98. Petersen RC, Smith GE, Waring SC, Ivink RJ, Tangalos EG, Kokmen E. Mild cognitive impairment. Clinical characterization and outcome. Arch Neural 56:303-308 (1999).
99. Rey A. L'examen clinique en psychologie.Paris: Presses Universitaires de France, 1964
100. Borod JC, Goodglass H, Kaplan E. Normative data on the Boston Diagnostic Aphasia Examination, Parietal Lobe battery and the Boston Naming Test. J Clin Neuropsychology 2:209-216 (1980).
101. Doty RL. The Smell Identification Test Administration Manual: 3rd Edition. In: Sensonics, Inc., Haddon Heights, New Jersy, USA., (1995).
102. Schosinsky KH, Lehmann HP, Beeler MF. Measurment of ceruloplasmin from its oxidase activity in serum by the use of odianisidine dihyydrochloride. Clin Chem 20(12):1556-1563 (1974).
103. Refolo LM, Pappolla MA, LaFrancois J, et al. A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol Dis. 8(5): 890-899 (2001).
104. Aisen PS, Schafer KA, Grundman M, et al. Effects of Rofecoxib or Naproxen vs placebo on Alzheimer disease progression. A randomized controlled trial. JAMA 289:2819-2826 (2003).
105. Aisen P. Randomized pilot study of nimesulide treatment in Alzheimer's disease. Neurology 58:1050-1054 (2002).
106. Aisen PS, Davis KL, Berg JD, et al. A randomized controlled trial of prednisone in Alzheimer's disease an Alzheimer's Disease Cooperative Study. Neurology 54:588-593 (2000).
107. Riemenschneider M, Lautenschlager N, Wagenpfeil S, Diehl J, Drzezga A, Kurz A. Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment. Arch Neural 59:1729-1734 (2002).
108. Maruyama M, Arai H, Sugita M, et al. Cerebrospinal fluid amyloid beta(1-42) levels in the mild cognitive impairment stage of Alzheimer's disease. Exp Neural 172:433-436 (2001).
109. de Leon MJ, Segal S, Tarshish CY, et al. Longitudinal cerebrospinal fluid tau load increases in mild cognitive impairment. Neurosci Lett 333:183-186 (2002).
110. Parnetti L, Lanari A, Saggese E, Spaccatini C, Gallai V. Cerebrospinal fluid biochemical markers in early detection and differential diagnosis of dementia disorders in routine clinical practice. Neurol Sci 24:199-200 (2003).
111. Fukumoto H, Tennis M, Locascio JJ, Hyman BT, Growdon JH, Irizarry. Age but not diagnosis is the main predictor of plasma amyloid β protein levels. Arch Neurol 60(7):958-964 (2003).
112. Assini A, Cammarata S, Vitali A, et al. Plasma levels of amyloid beta-protein 42 are increased in women with mild cognitive impairment. Neurology 63:828-831 (2004).
113. Sparks DL, Connor D, Lopez J, et al. Benefit of atorvastatin in the treatment of Alzheimer's Disease. Neurobiol Aging 25(suppl 1):S24 (2004).
114. DeMattos RB, Bales KR, Parsadanian M, etal. Plaque-associated disruption of CSF and plasma amyloid-beta (Abeta) equilibrium in a mouse model of Alzheimer's disease. J Neurochem 81(2):229-236 (2002).
115. DeMattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM. Brain to plasma amyloid-beta efflux: A measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 295:2264-2267 (2002).
116. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 98(15):8850-8855 (2001).